Peter is the Scientific Programme Lead for ESACT-UK having joined the committee in 2017 as an ordinary member. Peter holds both an undergraduate degree (BSc) in Human Biology and PhD in Regenerative Medicine from Loughborough University. After completing his PhD, he joined GlaxoSmithKline (GSK) in November 2015 as a ‘Senior Scientist’ in the Cell & Gene Therapy (C>) Upstream Vector Process Development team, and in November 2019 he was promoted to the role of ‘Investigator’. In these roles, he worked on the development of scalable upstream manufacturing processes for viral vectors. In 2020, he became the Team Lead for the C> Upstream Vector Process Development team at GSK, managing a team of scientists focused on the development and tech transfer of upstream processes for viral vectors.
Rhian is a Group Lead in the Process Research and Development Group at Oxford Biomedica. Oxford Biomedica is a leading, fully integrated, cell and gene therapy group, and has recently diversified in to the large-scale manufacturing of the adenoviral based COVID-19 vaccine. Rhian joined Oxford Biomedica in 2013, and helped to develop the first commercially approved LentiVector® process for the production Kymriah®. In addition, Rhian has guided the process development and tech transfer activities for clinical manufacture of numerous other cell and gene therapy candidates for multiple collaborators and clients. Prior to joining Oxford Biomedica, Rhian completed a Post-doctoral Research Associate position at the University of Cambridge. Rhian has been an active member of the ESACT-UK committee since 2010.
Petra is a Lecturer in Biochemical Engineering – Cellular agriculture at UCL. Previously, she was affiliated with Aston University. She holds a BEng in biochemical engineering (Romania) and a PhD in Regenerative Medicine from Loughborough University. Petra’s research interests lie at the intersection of Engineering and Life Sciences. Her multidisciplinary strengths and expertise include an understanding of the whole cell culture bioprocess from inoculation to harvest. Petra is a committee member of the ESACT-UK and also a committee member and travel bursary secretary for the Biochemical Engineering Subject Interest Group (BESIG) in the Institution of Chemical Engineers (IChemE) and a member of the IBLF (Industrial Biotechnology Leadership Forum). She is also on the Editorial Board of Biotechnology Letters and the winner of the ESACT-UK Inaugural Chris Hewitt Rising Star Award.
Hirra is the Secretary of ESACT-UK and joined the committee in 2017. Hirra completed her PhD in Biotechnology at the University of Manchester in 2016. After her PhD, she worked as a post-doctoral researcher at the Manchester Institute of Biotechnology with different industrial collaborators (Absynth Biologics Ltd and UCB Pharma). Both PhD and post-doctoral projects have concentrated on the molecular understanding of poor recombinant protein production and the use of engineering strategies to overcome this challenge. In July 2021, Hirra moved to the Centre for Process Innovation as a Senior Scientist in the Upstream Processing team at the National Biologics Manufacturing Centre. In this role, she continues to work on the development and production of different biopharmaceuticals including viral vectors and nucleic-acid based products.
Pavlos Kotidis leads the Digital Data and Analytics group in the Biopharm Process Research department of GSK, that focuses on the development of digital solutions for data exploration and platform improvement, leveraging multiple modelling and visualization approaches. Pavlos holds a PhD in Chemical Engineering from Imperial College London, during which he worked on optimising CHO-based biopharmaceutical production and recombinant antibody glycosylation. Pavlos has co-authored 13 research papers and 3 book chapters.
Rosalyn is the ESACT-UK trade coordinator, and her role involves registering trade delegates and organising the exhibition and sponsorships for the annual conference. She joined the committee in 2007, initially taking on the scientific programme coordinator role and then switching to the trade coordinator role in 2010, the role which she continues to date. At the University of Kent in Canterbury Rosalyn is an academic in the School of Biosciences and the Centre Manager and Administrator for the Industrial Biotechnology Centre. Her research interest is focused around the bioprocessing area in improving recombinant protein production from in vitro cultured mammalian cells. Projects focus upon identifying the cellular limitations with regard to recombinant protein production.
Leon Pybus is a member of the Bioprocess Strategy & Development team for FUJIFILM Diosynth Biotechnologies UK, leading development of the companies next generation CHO expression system and upstream processing technologies that improve and assist customers with the manufacture of therapeutic recombinant proteins. Leon holds a PhD from The University of Sheffield and has worked in the field of cell culture biotechnology for over 10 years.
Qasim is the Webmaster for ESACT-UK having previously served as the Society’s Secretary from 2015 – 2017 and the Scientific Programme Lead from 2017 – 2019. He is an Associate Professor in Cell and Gene Therapy Bioprocess Engineering at University College London (UCL). He is a multidisciplinary engineer working at the life science, engineering and commercial interfaces with a research focus on the bioprocessing, automation and biomanufacture of cell and gene-based therapies. He is Programme Director of a new MSc programme in the Manufacture and Commercialisation of Stem Cell and Gene Therapies. Qasim is both a Chartered Engineer and Chartered Scientist. He sits on multiple scientific committees including the IChemE Biochemical Engineering Subject Interest Group, British Standards Institute Biotechnology Committee and the BIA’s Cell & Gene Therapy Advisory Committee.
Rebecca is the social media team lead and joined the committee in 2023. Rebecca graduated from the University of York in 2020 with a first-class honours degree in Biology, and is now completing a PhD in Biotechnology in partnership with industrial sponsor, Fujifilm Diosynth Biotechnologies. Her project aims to investigate novel barriers that can enhance transgene expression from in vitro cultured mammalian cells. During her PhD, Rebecca has gained expertise in gene expression and epigenetics, and has co-authored 3 papers.
Eirini obtained a Diploma in Chemical Engineering from the National Technical University of Athens, followed by an MSc in Biochemical Engineering from University College London and a PhD in Biotechnology from the Technical University of Denmark (DTU). She worked as a Senior R&D scientist and Purification team leader at Xellia Pharmaceuticals, before returning to academia, and is currently a Senior Lecturer in Chemical and Biochemical Engineering at Aston University. She is a Senior Fellow of the Higher Education Academy, committee member for ESACT-UK and IChemE’s Biochemical Engineering Special Interest Group, and honorary Senior Research Fellow at the Royal Orthopaedic Hospital NHS Foundation Trust. Eirini’s research is in the areas of Healthcare and Cellular Agriculture, including the development of methods for the selective separation of human cells for clinical applications, and the creation of polymer-based scaffolds for tissue regeneration and animal stem cell expansion and differentiation.
Mauro is a Research Associate at the Manchester Institute of Biotechnology (University of Manchester) where his research focuses on mammalian cell bioprocessing and applications of synthetic biology to redesign biological systems. Collaborating with FUJIFILM Diosynth Biotechnologies UK, he is advancing the next-gen CHO expression system. Mauro holds a PhD in Molecular Biology (University of Manchester) and earned a BSc degree in Chemical Engineering from TU Braunschweig (Germany) and PUCV (Chile).